<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437748</url>
  </required_header>
  <id_info>
    <org_study_id>629CEC</org_study_id>
    <nct_id>NCT01437748</nct_id>
  </id_info>
  <brief_title>Closing Volume Interpretation and Bronchodilators Effect</brief_title>
  <official_title>Small Airways Evaluation and Peripherical Effect of Two Bronchodilators in Healthy Subjects and Stable COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The gold standard measures to evaluate small airways (SAW) &quot;in vivo&quot; is not well
           understood

        -  Two tests are today used to measure SAW but real results concordance is not clear

        -  These problems have a small evidence

        -  Data about real effect of bronchodilators on SAW (eg Tiotropium and Indacaterol) has
           never been studied

        -  Only an acute bronchodilators effect, after one hour of drugs inhalation, will be
           evaluated

        -  The time frame of study evaluations per patient will be of three hours: one hour for
           basal test; one hour rest after drug administration; one hour for post bronchodilators
           test

        -  All enrolled subjects will be outpatients and will be evaluated after 24 hours of
           inhalatory drugs washout
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of small airways both in healthy and Chronic Obstructive Pulmonary Disease
      (COPD)subjects still today remains a big problem with implications in diagnostic and clinical
      management. The first lung alteration in smokers is the bronchiolitis and possibility to
      understand real damage on this anatomical district should be very interesting. The first
      point of the study will be the SAW evaluation. The two principal technics to do this are:
      Single Breath Test (SBT) and oesophageal balloon (EB). With SBT is possible to obtain the
      four expiration phases and so the shift from phase 3 to phase 4 identifying the point called
      closing capacity (CC). With EB is possible to obtain the lung static pressure-volume curve
      and after this to identify the point of closing volume (CV). The real concordance of CC and
      CV has never been studied both in healthy and COPD subjects.

      The SBT is performed by pneumotachograph matched with a gas analyzer. Patient breath normally
      for some seconds, exhales to residual volume (RV) and after that deeply inhales oxygen (100%)
      to total lung capacity (TLC), then the patient exhales slowly to RV. This test will be
      repeated a minimum of three times.

      The evaluation of CV will be performed by EB. The oesophageal balloon is introduced by nose
      and located in distal oesophageal tract. By pressure transducer the correct position will be
      confirmed. After the investigators will perform the evaluation of lung volume, trans pleural
      pressure and flow. These parameters will be registered at tidal volume, during forced
      expiration and finally during hyperventilation.

      So, after the identification of presence,absence and eventually concordance of CC and CV
      should be interesting to evaluate the possible effect on SAW of bronchodilators usually used
      in clinical practice. More in detail, the investigators will administered in random order and
      after basal evaluation of CV and CC dry powder of indacaterol 300 micrograms (mcg) or
      Tiotropium 18 mcg. After one hour of drug administration the investigators will repeat the
      maneuver for CC and CV evaluations. In this way, will be evaluated only the acute effect of
      the bronchodilators on lung hyperinflation. Each subjects will perform plethysmographic test
      too. Bronchodilators will be administered only to the COPD patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Closing Volume (CV)</measure>
    <time_frame>Participants will be followed for the duration of medical office stay an expected average of 3 hours. The outcome measure will be assessed for the end of october 2011 and will be presented within december 2011.</time_frame>
    <description>The evaluation of CV will be performed by EB. The oesophageal balloon is introduced by nose and located in distal oesophageal tract. By pressure transducer the correct position will be confirmed. After the investigators will perform the evaluation of lung volume, trans pleural pressure and flow. These parameters will be registered at tidal volume, during forced expiration and finally during hyperventilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Closing Capacity (CC)</measure>
    <time_frame>Participants will be followed for the duration of medical office stay an expected average of 3 hours. The outcome measure will be assessed for the end of october 2011 and will be presented within december 2011</time_frame>
    <description>The evaluation of CC will be measuired by Single Breath Test (SBT) and performed by pneumotachograph matched with a gas analyzer. Patient breath normally for some seconds, exhales to residual volume (RV) and after that deeply inhales oxygen (100%) to total lung capacity (TLC), then the patient exhales slowly to RV. This test will be repeated a minimum of three times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Tiotropium or Indacaterol on CV and CC registration</measure>
    <time_frame>Participants will be followed for the duration of medical office stay an expected average of 3 hours. The outcome measure will be assessed for the end of october 2011 and will be presented within december 2011</time_frame>
    <description>Possible effect on small airways by two distinct ultra long acting bronchodilators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison concordance of CV and CC</measure>
    <time_frame>Participants will be followed for the duration of medical office stay an expected average of 3 hours. The outcome measure will be assessed for the end of october 2011 and will be presented within december 2011</time_frame>
    <description>This data will be important to identify the best, easiest and most reliable test for clinical SAW evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Indacaterol maleate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 300 mcg via Breezehaler Inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium bromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium 18 mcg, via HandiHaler inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol maleate</intervention_name>
    <description>Dry powder, 300 mcg, only one inhalation with 24 hours duration</description>
    <arm_group_label>Indacaterol maleate</arm_group_label>
    <other_name>Onbrez, Hirobriz, Onbrize, Oslif Breezehaler, Arcapta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide</intervention_name>
    <description>Dry powder, 18 mcg, only one inhalation with 24 hours duration</description>
    <arm_group_label>Tiotropium bromide</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of informed consent

          -  Healthy subjects with age from 20 to 80 yars old and never smokers

          -  COPD diagnosis

          -  COPD with age from 50 to 85 years old

          -  History of COPD at least of noe year

          -  Respiratory stable conditions at least of one month

          -  Any basal FEV1 expressed in % of predicted value

          -  FEV1/Forced Vital Capacity (FVC) less than 70%

          -  COPD with history of former or active smokers with minimum of 20 pack year

        Exclusion Criteria:

          -  Pregnancy

          -  FEV1/FVC more than 70%

          -  Known deficit of alpha 1 antitrypsin

          -  Subjects submitted to a Lung Volume Reduction Surgery (LVRS)

          -  Subjects with known positivity to Human Immunodeficiency Virus (HIV)

          -  Known intolerance to a nasogastric balloon

          -  Misuse of alcool or drugs

          -  Absence of compliance in performing respiratory test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierachille Santus, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universit√† degli Studi di Milano-Pneumologia Riabilitativa-Fondazione Salvatore Maugeri-MILANO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pneumologia Riabilitativa-Fondazione Maugeri-Istituto Scientifico di Milano- IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Pierachille Santus</investigator_full_name>
    <investigator_title>Head of Respiratory Rehabilitation Unit</investigator_title>
  </responsible_party>
  <keyword>Small Airways</keyword>
  <keyword>Closing volume</keyword>
  <keyword>Closing Capacity</keyword>
  <keyword>Tiotropium</keyword>
  <keyword>Indacaterol</keyword>
  <keyword>COPD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

